Study guide

12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications

Nutritionist-Dietitian Licensure Examination NDLE

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Licensure Law, Ethics, and the Clinical Nutritionist-Dietitian

1.1 NDLE Format, Scoring Rules, and RA 10862 Licensure Requirements 1.2 Scope of Practice, Professional Ethics, and Discipline under RA 10862 1.3 Role of the Clinical Nutritionist-Dietitian, Diet Orders, and Standard Hospital Diets

2 Chapter 2: Anatomy and Physiology for Nutrition I

2.1 Cells, Tissues, Membranes, and the Immune and Lymphatic Systems 2.2 The Digestive System: Organs, Enzymes, GI Hormones, and the Liver 2.3 Endocrine and Nervous System Regulation of Metabolism and Appetite

3 Chapter 3: Anatomy and Physiology II, Energy, and Carbohydrate Metabolism

3.1 Cardiovascular, Respiratory, Renal, Musculoskeletal, and Reproductive Systems 3.2 Energy Metabolism and Energy Expenditure Calculations 3.3 Carbohydrate Chemistry, Digestion, and Glycemic Pathways

4 Chapter 4: Protein, Lipid, Mineral, and Fluid Biochemistry

4.1 Protein Chemistry, Amino Acid Metabolism, and Nitrogen Balance 4.2 Lipid Metabolism, Lipoproteins, and Cardiovascular Biomarkers 4.3 Minerals, Water, Electrolytes, and Acid-Base Balance

5 Chapter 5: Basic Nutrition: Vitamins, Minerals, and the PDRI

5.1 Vitamin Biochemistry: Coenzyme Functions and Deficiency Syndromes 5.2 Vitamins and Minerals: PDRI Values, Food Sources, Bioavailability, Stability, and Toxicity 5.3 Philippine Dietary Reference Intakes (PDRI 2015), Pinggang Pinoy, and Dietary Guidelines

6 Chapter 6: Diet Computation and Clinical Nutrition Assessment

6.1 Food Exchange Lists, Meal Plan Computation, Food Labels, and Nutrient Density 6.2 Computing Desirable Body Weight, Total Energy Requirement, and the Diet Prescription 6.3 ABCD Methods of Clinical Nutrition Assessment

7 Chapter 7: Nutrition Diagnosis, Life-Stage Assessment, and Laboratory Data

7.1 Nutrition Diagnosis, PES Statements, and Medical Record Documentation 7.2 Pediatric, Obstetric, and Geriatric Clinical Nutritional Assessment 7.3 Interpreting Biochemical and Laboratory Data in Nutrition Assessment

8 Chapter 8: Drug-Nutrient Interactions, Diabetes, and Weight Disorders

8.1 Drug-Nutrient Interactions and Nutrient Depletion 8.2 MNT for Diabetes Mellitus and Endocrine Disorders 8.3 MNT for Overweight, Obesity, and Underweight

9 Chapter 9: MNT for Cardiovascular, Renal, and Gastrointestinal Disease

9.1 MNT for Cardiovascular Disease, Hypertension, and Dyslipidemia 9.2 MNT for Renal Diseases (AKI, CKD Stages 1-5, Dialysis, and Nephrotic Syndrome) 9.3 MNT for Disorders of the Gastrointestinal Tract

10 Chapter 10: MNT for Liver, Infectious, Respiratory, Allergic, and Neurologic Conditions

10.1 MNT for Liver, Gallbladder, and Pancreatic Disorders 10.2 MNT for Fevers, Infections, Diarrheal Disease, and Respiratory Disorders 10.3 MNT for Food Allergy and Intolerance, Skin, Rheumatic, Musculoskeletal, and Neurologic Disorders

11 Chapter 11: Critical Illness, Oncology, HIV, and Protein-Energy Malnutrition

11.1 MNT in Critical Illness, Sepsis, Trauma, and Burns 11.2 MNT in Oncology: Cancer Cachexia and Treatment Side Effects 11.3 MNT for HIV/AIDS and for Protein-Energy Malnutrition in Children and Adults

12 Chapter 12: Metabolic Disorders, Dysphagia, and Enteral Nutrition

12.1 MNT for Inborn Errors of Metabolism and Eating Disorders 12.2 Dysphagia, IDDSI Texture-Modified Diets, and Adaptive Feeding 12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications

13 Chapter 13: Parenteral Nutrition, Refeeding, and Nutrition Counseling

13.1 Parenteral Nutrition: Indications, Access, Substrates, and Compounding 13.2 Refeeding Syndrome and Complications of Parenteral Nutrition 13.3 Nutrition Counseling and Behavior Change Theories

14 Chapter 14: Nutrition Updates: Supplements, Diet Trends, and Sports Nutrition

14.1 Dietary Supplements, Herbal Medicines, and Functional Foods 14.2 Vegetarian Diets, Protein Complementation, and Popular Diet Trends 14.3 Sports Nutrition and Workplace Wellness Programs

15 Chapter 15: Community Nutrition and Population Assessment

15.1 Community Nutrition Principles, the ND's Roles, and the Philippine Health Delivery System 15.2 Nutritional Epidemiology and Health Status Indicators in the Philippines 15.3 Assessment of Community Nutritional Status and Operation Timbang Plus (OPT+)

16 Chapter 16: Dietary Surveys, Nutrition Research, and Surveillance

16.1 Food Consumption Surveys, Biochemical Tests in Surveys, and Clinical Signs of Deficiency 16.2 Food and Nutrition Research Methods, Sampling, Sample Size, and Research Ethics 16.3 National Nutrition Surveys, Demographic Data, and Designing a Nutrition Surveillance System

17 Chapter 17: Nutrition Education and Program Evaluation

17.1 Nutrition Education: Definition, Principles of Learning, Methods, and Teaching Aids 17.2 Designing a Nutrition Education Program and Measuring Customer Satisfaction 17.3 Program Planning Cycle, SMART Objectives, and Types of Evaluation

18 Chapter 18: Program Planning, Interventions, and Food Security

18.1 Nutrition Program Planning: Needs, Priorities, Constraints, Goals, and Using Evaluation Results 18.2 Nutrition Interventions and Programs for Specific Population Groups 18.3 Food and Nutrition Security, Dietary Diversity, and Vulnerable Populations

19 Chapter 19: Nutrition Governance, Networking, and Program History

19.1 National Nutrition Council (NNC) Structure and Philippine Plan of Action for Nutrition (PPAN) 19.2 Nutrition Agencies, Networking, Community Linkages, Teamwork, and Nutrition Legislation 19.3 Development of Philippine Nutrition Programs and the Country's Nutrition Problems

20 Chapter 20: Fortification, Feeding, and First 1,000 Days Laws

20.1 Food Fortification (RA 8976), Salt Iodization (RA 8172), and the 2024 Salt Industry Law 20.2 Supplementary Feeding Programs (RA 11037) and DSWD/DepEd Interventions 20.3 First 1,000 Days Law (RA 11148) and Maternal-Child Interventions

21 Chapter 21: Nutrition in the Life Cycle I

21.1 Infant and Young Child Feeding (IYCF), Philippine Milk Code (EO 51), and RA 10028 21.2 Nutrition in Pregnancy and Lactation: Physiology, Needs, Meal Patterns, and Problems 21.3 Nutrition from Infancy to School Age: Growth, Feeding Patterns, Problems, and School Programs

22 Chapter 22: Nutrition in the Life Cycle II

22.1 Nutrition for Adolescents and Adults: Growth Spurt, Risk Factors, and NCD Prevention 22.2 Nutrition for Older Adults: Aging Changes, Needs, Problems, and Senior Citizen Programs

23 Chapter 23: Food Science and Plant Foods

23.1 Chemistry of Starches, Proteins, Lipids, and Emulsions in Cooking 23.2 Food Pigments, Flavor Chemistry, and Browning Reactions (Maillard & Enzymatic) 23.3 Fruits, Vegetables, and Legumes: Classification, Market Forms, Quality, Storage, and Cookery

24 Chapter 24: Animal Foods, Cereals and Baking, and Cooking Methods

24.1 Meat, Poultry, Fish, Eggs, and Milk: Structure, Quality, Storage, and Cookery 24.2 Cereals, Flour Mixtures and Baking, Sugar Cookery, Fats and Oils, and Beverages 24.3 Heat Transfer, Dry-Heat and Moist-Heat Cooking Methods, and Filipino Cooking Techniques

25 Chapter 25: Culinary Skills, Family Meal Planning, and Food Quality

25.1 Culinary Vocabulary, Knife Cuts, Basic Sauces, and Accurate Measurement 25.2 Meal Planning for the Family, Food Budgeting, and Recipe Development 25.3 Sensory Evaluation, Objective Food Tests, and Quality Assurance in Food Production

26 Chapter 26: Food Microbiology, Preservation, and Food Law

26.1 Foodborne Pathogens, Microbial Kinetics, and FAT TOM Parameters 26.2 Food Preservation Methods, Thermal Processing, and Packaging 26.3 Philippine Food Laws, Regulatory Agencies, and Food Labeling

27 Chapter 27: Sanitation, HACCP, Waste, and Workplace Safety

27.1 Sanitation Standard Operating Procedures (SSOP) and Good Manufacturing Practices (GMP) 27.2 HACCP Principles and Critical Control Point Management in Food Service 27.3 Waste Management, Pest Control Regulation, and Occupational Safety in Food Service

28 Chapter 28: Food Service Systems, Production Planning, and Menus

28.1 Types of Food Service Delivery Systems (Conventional, Ready-Prepared, Commissary, Assembly) 28.2 Forecasting, Production Planning, and Quantity Food Production Techniques 28.3 Institutional Menu Planning, Modified Diets, and Recipe Standardization

29 Chapter 29: Distribution, Purchasing, and Storage

29.1 Food Distribution and Service Systems in Hospitals and Other Institutions 29.2 Food Purchasing Methods, Specifications, and Receiving 29.3 Storage Management, Inventory Control, and Valuation

30 Chapter 30: Cost Control, Financial Management, and Facility Layout

30.1 Food Cost Accounting, Yield Testing, and Portion Control Formulas 30.2 Menu Pricing Models, Break-Even Analysis, and Financial Statements 30.3 Food Service Facility Layout, Equipment Selection, and Workflow Ergonomics

31 Chapter 31: Equipment, Management, and Human Resources

31.1 Food Service Equipment: Selection, Capacity, Life-Cycle Cost, Depreciation, and Maintenance 31.2 Management Functions, Theories, Leadership Styles, and Managing Change in Food Service 31.3 Human Resource Management: Job Design, Recruitment, Training, Appraisal, and Discipline

32 Chapter 32: Labor Law, Permits, and Food Service Marketing

32.1 Philippine Labor Laws and Business Permits for Food Service Operations 32.2 Food Service Marketing, Menu Engineering, and Sustainable Food Service

12.3 Enteral Nutrition: Indications, Formula Selection, Access Routes, and Complications

Key Takeaways Explain This Topic AI

The core clinical axiom 'If the gut works, use it' preserves gut mucosal architecture, sustains enterocyte tight junctions, stimulates Gut-Associated Lymphoid Tissue (GALT), and produces secretory IgA, preventing pathogenic bacterial translocation and systemic sepsis.

Enteral access selection depends on duration and aspiration risk: short-term (<4–6 weeks) feeding utilizes nasogastric (NG) or post-pyloric (ND/NJ) tubes, whereas long-term (>4–6 weeks) access requires percutaneous endoscopic gastrostomy (PEG) or jejunostomy (PEJ).

Elemental and semi-elemental formulations contain hydrolyzed peptides or free amino acids with high Medium-Chain Triglyceride (MCT) fractions that absorb directly into the portal vein without requiring pancreatic lipase or bile salt micellar incorporation.

Disease-tailored formulas address specific organ failures: concentrated low-electrolyte formulations for renal failure, high-fat/low-carbohydrate blends to reduce CO2 production (lower RQ) in respiratory failure, and BCAA-enriched formulations to normalize the Fischer ratio in refractory hepatic encephalopathy.

Gastrointestinal complication protocols prioritize ruling out Clostridioides difficile toxin and liquid medication sorbitol in enteral diarrhea, elevating the head of the bed to 30°–45°, and eliminating routine cessation of feeds for asymptomatic Gastric Residual Volumes (GRVs) below 500 mL.

Last updated: October 2026

Enteral Nutrition (EN) involves the delivery of specialized nutritional formulas directly into the gastrointestinal tract via a tube, catheter, or stoma distal to the oral cavity. In clinical dietetics and the NDLE , EN is recognized as the standard of care for patients who possess a functioning gastrointestinal tract but are unable to meet their nutritional requirements through volitional oral intake.

The Physiological Supremacy of the Gut: "If the Gut Works, Use It"

The clinical directive "If the gut works, use it" is grounded in clear gastrointestinal physiology and immunology. Total bowel disuse triggers rapid mucosal atrophy within 48 to 72 hours, resulting in devastating systemic consequences: Luminal Nutrients Present

  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ ▼
  • [Structural Integrity] [Immunological Defense]
  • Direct enterocyte fuel (glutamine, butyrate) - GALT activation (>70% body immunity)
  • Sustained villous height & surface area - Secretory IgA (sIgA) synthesis
  • Preserved tight junctions (claudin, occludin) - Mucosal pathogen neutralization
  • │ │
  • └────────────────────────┬────────────────────────┘
  • ▼

Barriers Intact & Sealed:

  • Prevention of Bacterial Translocation & Endotoxemia
  • Attenuated Hypermetabolic Stress & MODS Prevention
  • 1. Maintenance of Mucosal Barrier Integrity

Enterocytes derive up to 70% of their energetic fuel directly from luminal nutrients rather than systemic circulation. The small intestinal mucosa utilizes luminal glutamine , while colonocytes metabolize bacterial-derived short-chain fatty acids (primarily butyrate) . In the absence of luminal nutrients:

Intestinal villi blunt, flatten, and atrophy.

Epithelial tight junctions (composed of occludins and claudins) loosen and disassemble.

Intestinal permeability increases drastically, allowing intraluminal bacteria (gram-negative enteric organisms such as Escherichia coli and Klebsiella ) and endotoxins (lipopolysaccharides [LPS]) to cross the mucosal basement membrane.

This phenomenon, termed bacterial translocation , allows pathogens to enter mesenteric lymph nodes, the thoracic duct, and portal blood, fueling systemic bacteremia, systemic inflammatory response syndrome (SIRS), and Multiple Organ Dysfunction Syndrome (MODS) .

2. Stimulation of Gut-Associated Lymphoid Tissue (GALT)

Over 70% of the body's total immune system resides within the gastrointestinal tract , configured as Gut-Associated Lymphoid Tissue (GALT) , including Peyer's patches, lamina propria lymphocytes, and intraepithelial lymphocytes. Luminal feeding stimulates GALT to produce Secretory Immunoglobulin A (sIgA) . Secretory IgA is actively transported across mucosal enterocytes into the gut lumen, where it binds and neutralizes pathogenic bacteria, viruses, and toxins, preventing mucosal adhesion and systemic invasion.

  • Indications and Contraindications for Enteral Feeding
  • Clinical Indications

Enteral nutrition is indicated when a patient cannot, will not, or should not consume adequate oral nutrients, provided the GI tract is functional:

Inability to meet ≥ 60 % \ge 60\% ≥ 60% of estimated caloric and protein needs orally for > 5 to 7 days >5\text{ to }7\text{ days} > 5 to 7 days in previously well-nourished patients, or > 3 to 5 days >3\text{ to }5\text{ days} > 3 to 5 days in malnourished patients.

Severe dysphagia secondary to neurologic disease (cerebrovascular accident, ALS, Guillain-Barré, Parkinson's disease).

Neoplasms or trauma of the oral cavity, pharynx, larynx, or esophagus.

Prolonged mechanical ventilation and critical illness.

Hypermetabolic states (severe burns, polytrauma, major head injury) where oral intake cannot match caloric demands.

Severe anorexia nervosa or severe failure to thrive.

Contraindications

Contraindication Category Clinical Condition Pathophysiologic Rationale

Absolute Complete mechanical bowel obstruction Feeding proximal to a complete physical block triggers severe dilation, emesis, ischemia, and perforation.

Absolute Severe short bowel syndrome ( < 100 cm <100\text{ cm} < 100 cm small bowel without colon; < 60 cm <60\text{ cm} < 60 cm with colon) Insufficient absorptive surface area; leads to massive diarrhea, dehydration, and electrolyte depletion.

Absolute Severe, generalized peritonitis Intestinal wall inflammation and paralysis negate absorptive capacity.

Absolute High-output enterocutaneous fistula ( > 500 mL/day >500\text{ mL/day} > 500 mL/day ) Luminal feeds bypass distal bowel and pour out through the fistula track, exacerbating fluid and electrolyte loss (unless feeding access exists distal to fistula).

Absolute / Hemodynamic Refractory septic shock requiring escalating high-dose vasopressors Splanchnic vasoconstriction reduces mesenteric perfusion. Luminal nutrients increase mucosal oxygen demand; inability to meet this demand triggers Non-Occlusive Mesenteric Ischemia (NOMI) and bowel infarction.

Relative Prolonged paralytic ileus Lack of peristalsis impairs formula progression (gastric ileus may still permit post-pyloric feeding).

Relative Intractable vomiting or diarrhea refractory to medical management Inability to retain or absorb enteral substrates.

Caution

Vasopressors and Enteral Nutrition: When a patient is in active shock requiring escalating or high doses of vasopressors (e.g., norepinephrine > 0.25 μ g/kg/min >0.25\ \mu\text{g/kg/min} > 0.25 μ g/kg/min or high-dose epinephrine), enteral nutrition must be withheld . Feedings should only be initiated once the patient is adequately fluid-resuscitated, mean arterial pressure (MAP) is maintained ≥ 65 mmHg \ge 65\text{ mmHg} ≥ 65 mmHg , and vasopressor requirements are stable or weaning.

Enteral Access Routes

The selection of an enteral feeding route depends upon two primary factors: the anticipated duration of therapy (threshold: 4 to 6 weeks) and the patient's risk of pulmonary aspiration . Anticipated Duration of EN

  • │
  • ┌───────────────────────┴───────────────────────┐
  • ▼ ▼
  • [Short-Term: <4–6 Weeks] [Long-Term: >4–6 Weeks]
  • │ │

Aspiration Risk? Aspiration Risk?

  • ┌───────┴───────┐ ┌───────┴───────┐
  • ▼ ▼ ▼ ▼
  • (Low) (High) (Low) (High)
  • Nasogastric Nasojejunal / Gastrostomy Jejunostomy
  • (NG) Nasoduodenal (NJ/ND) (PEG) (PEJ)
  • 1. Short-Term Access Routes ( < 4 to 6 Weeks <4\text{ to }6\text{ Weeks} < 4 to 6 Weeks )

Nasogastric (NG) Tube: Passes through the nose, traversing the esophagus into the stomach. Indicated for patients with intact gastric motility, normal gag reflex, and low aspiration risk. It accommodates all delivery methods (bolus, intermittent, continuous) and takes advantage of normal gastric digestive and antimicrobial reservoir functions.

Nasoduodenal (ND) and Nasojejunal (NJ) Tubes: Pass through the nose, stomach, and pylorus, terminating in the duodenum or jejunum (distal to the ligament of Treitz). Post-pyloric feeding is indicated for:

High pulmonary aspiration risk (severe gastroesophageal reflux, blunted cough/gag reflexes, depressed consciousness).

Persistent gastroparesis or delayed gastric emptying.

Severe acute pancreatitis (feeding distal to the ligament of Treitz eliminates the cephalic and gastric phases of pancreatic secretion, keeping the exocrine pancreas at rest).

Gastric outlet obstruction.

2. Long-Term Access Routes ( > 4 to 6 Weeks >4\text{ to }6\text{ Weeks} > 4 to 6 Weeks )

Percutaneous Endoscopic Gastrostomy (PEG): Placed directly into the stomach through the anterior abdominal wall under endoscopic guidance. Standard for long-term enteral feeding. Comfortable, hidden under clothing, preserves normal gastric reservoir physiology, and permits bolus or gravity feedings.

Percutaneous Endoscopic Jejunostomy (PEJ) / Direct Jejunostomy: Placed directly into the jejunum. Indicated when gastric feeding is contraindicated long-term (gastric carcinoma, prior subtotal/total gastrectomy, severe persistent gastroparesis, recurrent aspiration via PEG). Strictly requires continuous pump infusion.

Important

Never Bolus Feed into the Small Intestine! The duodenum and jejunum lack an expandable reservoir and the regulatory control of the pyloric sphincter. Delivering rapid bolus feeds directly into the jejunum causes rapid intestinal distension and hyperosmolar fluid influx, triggering severe abdominal cramping, nausea, diaphoresis, and explosive osmotic dumping syndrome . All post-pyloric feeds (ND, NJ, PEJ) must be administered via continuous pump infusion .

Enteral Formula Classifications and Selection

Commercial enteral formulas are formulated with distinct carbohydrate, protein, lipid, and caloric profiles to match varied gastrointestinal and metabolic capacities: Enteral Formula Spectrum

  • │
  • ┌───────────────────────────────┼───────────────────────────────┐
  • ▼ ▼ ▼
  • [Polymeric / Standard] [Elemental / Monomeric] [Disease-Specific]
  • Intact proteins - Free amino acids / peptides - Renal (Nepro: high kcal, low lytes)
  • 1.0–1.2 kcal/mL - MCT-rich lipid fraction - Pulmonary (high fat, low carb)
  • Isosmolal (~300 mOsm) - Hyperosmolar (>500 mOsm) - Diabetes (low GI carb, high MUFA)
  • Normal digestion - Malabsorptive disorders - Hepatic (high BCAA, low AAA)
  • 1. Polymeric (Standard) Formulations

Macronutrient Composition: Intact protein isolates (caseinates, whey protein, soy protein); complex carbohydrates (maltodextrin, corn syrup solids, hydrolyzed cornstarch); long-chain triglycerides (canola, corn, soy, or sunflower oils).

Characteristics: Caloric density of 1.0 to 1.2 kcal/mL 1.0\text{ to }1.2\text{ kcal/mL} 1.0 to 1.2 kcal/mL ; protein content 30–45 g/L; isosmolal ( ≈ 300 to 400 mOsm/kg \approx 300\text{ to }400\text{ mOsm/kg} ≈ 300 to 400 mOsm/kg ); provides approximately 80% to 85% free water.

Clinical Indications: Patients with intact digestive and absorptive capacities who require supplemental or total nutrition support.

2. Concentrated / Calorie-Dense Formulations

Characteristics: Caloric density of 1.5 to 2.0 kcal/mL 1.5\text{ to }2.0\text{ kcal/mL} 1.5 to 2.0 kcal/mL ; high protein content (60–90 g/L); reduced free water content ( 68 % to 76 % 68\%\text{ to }76\% 68% to 76% ).

Clinical Indications: Severe fluid-restricted states: Congestive Heart Failure (CHF), oliguric Acute Kidney Injury (AKI) or Chronic Kidney Disease (CKD), Syndrome of Inappropriate Antidiuretic Hormone (SIADH), severe peripheral/pulmonary edema.

3. Elemental (Monomeric) and Semi-Elemental (Oligomeric) Formulations

Macronutrient Composition: Hydrolyzed peptides (di- and tri-peptides, which are absorbed more rapidly and efficiently via the enterocyte PepT1 transporter than free amino acids) or pure crystalline free L-amino acids. Carbohydrates are provided as short-chain maltodextrins or glucose oligosaccharides.

Lipid Fraction & Medium-Chain Triglycerides (MCTs): Contains minimal long-chain triglycerides (LCTs) and a high fraction of MCTs ( C 8 to C 10 C_8\text{ to }C_{10} C 8 ​ to C 10 ​ , caprylic and capric acids) . MCTs possess unique biochemical properties:

They are water-soluble and can be absorbed directly across enterocyte membranes without requiring emulsification by bile salts or cleavage by pancreatic lipase.

They do not form chylomicrons and do not traverse the thoracic duct; instead, they absorb directly into the portal vein bound to albumin, traveling directly to the liver.

Characteristics: Hyperosmolar ( 450 to 700 + mOsm/kg 450\text{ to }700+\text{ mOsm/kg} 450 to 700 + mOsm/kg ); requires slow initial infusion rates to prevent osmotic diarrhea.

Clinical Indications: Severe malabsorption syndromes, Short Bowel Syndrome, chronic pancreatitis with pancreatic exocrine insufficiency, severe Crohn's disease exacerbation, radiation enteritis, chylothorax, and chylous ascites.

4. Disease-Specific Specialized Formulations

Clinical Condition Specialized Formula Characteristics Biochemical / Physiological Rationale

Renal Disease (Pre-Dialysis: CKD 3–5) Concentrated ( 1.8 – 2.0 kcal/mL 1.8–2.0\text{ kcal/mL} 1.8–2.0 kcal/mL ); low protein ( 0.6 – 0.8 g/kg 0.6–0.8\text{ g/kg} 0.6–0.8 g/kg , ~8–10% kcal); severely restricted in potassium, phosphorus, and sodium. Restricts fluid; minimizes accumulation of nitrogenous uremic toxins (BUN) while controlling electrolyte retention.

Renal Disease (Dialysis: HD / PD) Concentrated ( 1.8 – 2.0 kcal/mL 1.8–2.0\text{ kcal/mL} 1.8–2.0 kcal/mL ); high protein ( 1.2 – 1.5 g/kg 1.2–1.5\text{ g/kg} 1.2–1.5 g/kg , ~18–20% kcal, e.g., Nepro); restricted in potassium, phosphorus, sodium. Restricts fluid and electrolytes, but supplies high protein to replenish massive amino acid and peptide losses across the dialyzer membrane.

Pulmonary Failure / Mechanical Ventilation Higher fat ( 45 – 55 % 45–55\% 45–55% of kcal) and lower carbohydrate ( 25 – 35 % 25–35\% 25–35% of kcal). Based on Respiratory Quotient ( R Q = VCO 2 / VO 2 RQ = \text{VCO}_2 / \text{VO}_2 RQ = VCO 2 ​ / VO 2 ​ ). Fat metabolism yields an R Q RQ RQ of 0.70 vs. 1.00 for carbohydrates. Lower carbohydrate reduces total C O 2 CO_2 C O 2 ​ production, lowering ventilatory workload. (Note: avoiding total overfeeding is clinically more critical).

Diabetes Mellitus / Glucose Intolerance Low glycemic index complex carbs, high Monounsaturated Fatty Acids (MUFA, ~60% of fat kcal) , enriched in soluble/insoluble fiber. Blunts postprandial glucose excursions, reduces HbA1c, improves insulin sensitivity, and prevents hypertriglyceridemia.

Hepatic Failure (Refractory Encephalopathy) Enriched in Branched-Chain Amino Acids (BCAA: leucine, isoleucine, valine) ; depleted in Aromatic Amino Acids (AAA: phenylalanine, tyrosine, tryptophan) . In advanced cirrhosis, the Fischer Ratio ( [ BCAA ] / [ AAA ] [\text{BCAA}]/[\text{AAA}] [ BCAA ] / [ AAA ] ) falls from 3.5:1 to < 1.0 : 1 <1.0:1 < 1.0 : 1 . Unopposed AAAs cross the blood-brain barrier via the LAT-1 carrier, synthesizing false neurotransmitters (octopamine, phenylethanolamine) that induce encephalopathy. BCAAs compete for LAT-1 transport, restoring balance.

Immune-Modulating Formulations Supplemented with arginine, glutamine, omega-3 fatty acids, and nucleic acids. Enhances T-lymphocyte function, improves surgical wound healing, and reduces infectious complications in major elective GI surgery and trauma. ( Caution: supplemental arginine is contraindicated in severe active septic shock due to excessive nitric oxide production).

Enteral Administration Modalities

Continuous Infusion:

Method: Administered continuously over 24 hours at a steady, controlled rate using an electronic volumetric infusion pump.

Indications: Critically ill patients, post-pyloric (duodenal or jejunal) feedings, patients experiencing gastrointestinal intolerance, or patients with unstable blood glucose.

Cyclic Infusion:

Method: Administered via infusion pump over a compressed time frame ( 8 to 16 hours 8\text{ to }16\text{ hours} 8 to 16 hours , typically overnight).

Indications: Promotes daytime mobility and rehabilitation; allows daytime appetite to return during the transition from tube feeding to oral diet.

Intermittent Gravity Drip:

Method: Infusion of 200 to 400 mL 200\text{ to }400\text{ mL} 200 to 400 mL of formula over 30 to 60 minutes 30\text{ to }60\text{ minutes} 30 to 60 minutes , repeated 4 to 6 times daily via a gravity flow bag.

Indications: Gastric feeding only; provides a regular meal-like pattern for stable rehabilitation patients.

Bolus Feeding:

Method: Rapid delivery of 200 to 400 mL 200\text{ to }400\text{ mL} 200 to 400 mL of formula over 10 to 20 minutes 10\text{ to }20\text{ minutes} 10 to 20 minutes using a 60-mL catheter-tip syringe by gravity or gentle plunger action, administered 4 to 6 times daily.

Indications: Strictly limited to gastric feeding (NG or PEG) in alert, stable patients with normal gastric emptying and intact gag reflex. Simulates physiological meal schedules and requires no expensive pump equipment.

  • Complications of Enteral Nutrition and Evidence-Based Management
  • 1. Gastrointestinal Complications: Enteral Diarrhea Workup

Diarrhea (defined as > 3 to 5 >3\text{ to }5 > 3 to 5 liquid stools/day or > 200 – 300 g/day >200–300\text{ g/day} > 200–300 g/day ) occurs in 15% to 30% of enterally fed patients. The clinical dietitian must execute an ordered, systematic diagnostic workup: Enteral Diarrhea Arises

  • │
  • ▼
  • [Step 1: Stool Microbiology Assay]
  • Test for Clostridioides difficile toxin
  • DO NOT give antimotility agents (loperamide)
  • │
  • ┌────────────────────────┴────────────────────────┐
  • ▼ (Positive) ▼ (Negative)
  • Initiate Vancomycin / [Step 2: Liquid Medication Audit]
  • Fidaxomicin Medical Rx Inspect elixirs for SORBITOL content
  • (e.g., acetaminophen, theophylline)
  • Audit antibiotics & magnesium antacids
  • │
  • ▼
  • [Step 3: EN Formula & Administration]
  • Check hang time (open: 8–12h, closed: 24–48h)
  • Slow the infusion rate
  • Add soluble fiber (guar gum, banana flakes)
  • Trial semi-elemental / peptide formula

Rule Out Clostridioides difficile : Never administer antidiarrheal antimotility agents (loperamide, diphenoxylate/atropine) before ruling out C. diff via stool PCR or toxin assay. Halting gut motility during active toxigenic C. diff colitis risks precipitating toxic megacolon and bowel perforation.

Medication Audit for Sorbitol: Liquid oral elixirs and syrups (acetaminophen, theophylline, furosemide, potassium chloride) frequently contain large amounts of sorbitol as an artificial sweetener/excipient. Ingestion of as little as 10 to 20 g/day 10\text{ to }20\text{ g/day} 10 to 20 g/day of sorbitol exerts a massive osmotic draw into the colonic lumen, producing severe iatrogenic osmotic diarrhea. Switch liquid medications to crushed tablets (if approved) or IV formulations.

Hang Time Hygiene: Contaminated enteral formula can cause infectious diarrhea. Open system containers (where formula is poured into a bag from cans) have a strict maximum hang time of 8 to 12 hours 8\text{ to }12\text{ hours} 8 to 12 hours . Closed, pre-filled, sterile ready-to-hang containers have a safe hang time of 24 to 48 hours 24\text{ to }48\text{ hours} 24 to 48 hours .

Fiber Modification: Adding soluble, fermentable fiber (partially hydrolyzed guar gum, pectin, banana flakes) provides substrates for colonic microflora to generate short-chain fatty acids (SCFAs). SCFAs stimulate colonic sodium and water reabsorption, firming liquid stools.

2. Gastric Residual Volume (GRV) Management and Aspiration Prevention

Aspiration Prevention: Pulmonary aspiration of gastric contents is the most hazardous complication of enteral nutrition. Maintain the Head of Bed (HOB) elevated at 30 ∘ to 45 ∘ 30^\circ\text{ to }45^\circ 3 0 ∘ to 4 5 ∘ at all times during feeding and for at least 30 to 60 minutes after intermittent feeds.

Modern GRV Consensus: Historic practices of holding feeds for GRVs of 150 to 200 mL are obsolete and lead to severe under-delivery of nutrition. Current ASPEN/SCCM guidelines state:

Routine monitoring of GRV is not recommended in ICU patients without overt signs of intolerance.

Where monitored, do not hold enteral feeding for GRVs < 500 mL <500\text{ mL} < 500 mL in the absence of other symptoms of GI intolerance (nausea, emesis, abdominal distension, absent bowel sounds).

If gastric intolerance occurs, consider advancing the tube post-pyloric or initiating a prokinetic agent ( metoclopramide 10 mg IV or erythromycin 100–250 mg IV).

3. Mechanical Complications: Tube Clogging

Etiology: Tube occlusion results from formula curdling, inadequate water flushing, or improper medication administration (mixing crushed tablets directly into the formula, or administering whole pills).

Prevention Protocol: Flush feeding tubes with 30 mL 30\text{ mL} 30 mL of warm tap or sterile water :

Every 4 hours during continuous feeding.

Before and after each intermittent or bolus feeding.

Before and after each individual medication administration (flush with 5–10 mL between medications).

Before and after checking gastric residual volumes.

Restoring Patency:

Instill warm water with a 30-mL or 60-mL syringe using a gentle push-pull plunger technique.

If water fails, instill an activated pancreatic enzyme mixture : crush one pancreatic enzyme tablet (e.g., Creon, Viokace) and dissolve with one 325-mg sodium bicarbonate tablet in 5–10 mL of warm water. Instill into the tube, clamp for 30 to 60 minutes, and flush with warm water.

PROHIBITED: Never instill acidic carbonated beverages (cola), cranberry juice, or meat tenderizers. The acid causes intact caseinate proteins in enteral formulas to precipitate immediately, creating an intractable, rock-hard intraluminal obstruction!